Oxolife’s CEO Agnès Arbat receives prestigious EU Women Innovators Prize
Barcelona, Spain – 9 April 2025: Oxolife, the female fertility biotech focused on increasing live birth rates by enhancing embryo implantation in women undergoing assisted reproductive technology (ART) fertility treatment, today announces that Agnès Arbat, its Chief Executive Officer, has been awarded the prestigious EU Women Innovators Prize at the European Innovation Council (EIC) Summit on the 3rd of April 2025 in Brussels, Belgium.
The EU Women Innovators Prize is open to women founders and co-founders from across the EU and countries associated to Horizon Europe, who have founded a successful company and brought innovation to the market. As part of the prize, Agnès has been awarded €100,000.
Agnès Arbat, Chief Executive Officer, Oxolife, said: “I am deeply honoured to receive this award among such an inspiring group of women innovators who are pushing boundaries and making a real impact. At Oxolife we are advancing our lead candidate to improve fertility, an area that is very close to my heart, so this recognition is especially rewarding. I am incredibly grateful to my dedicated team at Oxolife, as well as our advisors, investors, and supporters. This achievement is a testament to the strength and commitment of our entire biotech family.”
Sara Secall, General Partner, Inveready “This is a well-deserved recognition for Agnès and the entire team at Oxolife. Women’s health remains a significantly underserved area in medicine, and it’s vital that we continue advancing solutions in this space. Agnès’ dedication to developing better fertility treatments is making a real difference, and this award is a testament to her vision, leadership, and unwavering commitment to improving care for women”
With over 20 years of experience in the pharmaceutical industry, Agnès has been responsible for the clinical development and management of Oxolife since its founding in 2013. Previously, she led the Women's Health and Cardiovascular medical team at Bayer and worked in Medical Affairs in Women’s Health at Organon. Agnès has played a key role in over 20 clinical studies in women’s health and has contributed to the launch of more than 10 new products or indications, including Xarelto, Nexplanon, and Ventavis. Agnès holds a medical degree from the Autonomous University of Barcelona with a specialty in Clinical Pharmacology and completed a General Management Programme at IESE Business School. She is a guest professor & mentor for the Master's in Pharmaceutical Industry and Biotechnology at UPF and UIC.
Oxolife’s lead candidate, OXO-001, is a first-in-class non-hormonal drug that acts directly on the endometrium to enhance and improve the embryo implantation process, a breakthrough innovation in reproductive medicine. A single-to-take oral tablet, OXO-001 has demonstrated its effectiveness in increasing embryo implantation, pregnancy, and live birth rates among infertile women who are undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
OXO-001 has successfully completed Phase 2 studies for its initial indication in embryo implantation and is ready to enter Phase 2 trials for a second indication, Polycystic Ovary Syndrome (PCOS), where it has shown promise in restoring ovulation and improving fertility.
